Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) announced today that the Korea Food and Drug Administration (KFDA) has awarded licensure to Quinvaxem™, a fully liquid pentavalent vaccine to be produced by Crucell in Korea. Quinvaxem™ was co-developed with Chiron Corporation, which provides four of the five components as bulk.
